Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Ferring

Status: Completed

Conditions: Advanced Prostate Cancer

Treatments: Drug: Degarelix; Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)

Study type: Observational

Funder types: Industry

Identifiers

NCT02234089

000156

Details and patient eligibility

About

The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).

Enrollment: 461 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
• Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment

Exclusion criteria

• Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
• Participation in a clinical trial at baseline and during the follow-up period

Trial design

461 participants in 2 patient groups

Degarelix

Treatment:

Drug: Degarelix

LHRH agonist

Treatment:

Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)